Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

Published:2018-02-02 Issue:4 Volume:103 Page:631-642
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Baverel Paul G.¹,Dubois Vincent F.S.¹,Jin Chao Yu²,Zheng Yanan²,Song Xuyang³,Jin Xiaoping³,Mukhopadhyay Pralay⁴,Gupta Ashok³,Dennis Phillip A.⁴,Ben Yong⁴,Vicini Paolo¹,Roskos Lorin³,Narwal Rajesh³

Affiliation:

1. MedImmuneCambridge UK

2. MedImmune, Mountain ViewCalifornia USA

3. MedImmuneGaithersburg Maryland USA

4. AstraZenecaGaithersburg Maryland USA

Funder

MedImmune

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.982

Reference33 articles.

1. PD-1 and PD-L1 antibodies in cancer: current status and future directions

2. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

3. Evaluation of dosing strategy for pembrolizumab for oncology indications

4. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors

5. Association of Time-Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study;Journal of Experimental & Clinical Cancer Research;2024-08-22

2. Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors;The Oncologist;2024-07-09

3. Time‐varying brentuximab vedotin pharmacokinetics and weight‐based dosing in paediatric patients despite lower exposure in those aged 2 to <6 and 6–11 years;British Journal of Clinical Pharmacology;2024-06-12

4. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma;Clinical and Translational Science;2024-05-29

5. Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer;CPT: Pharmacometrics & Systems Pharmacology;2024-05-06